» Articles » PMID: 2846900

Implications of Methadone Maintenance for Theories of Narcotic Addiction

Overview
Journal JAMA
Specialty General Medicine
Date 1988 Nov 25
PMID 2846900
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical success in rehabilitation of heroin addicts with maintenance treatment requires stability of the blood level in a pharmacologically effective range (optimally, 150 to 600 ng/mL)-a phenomenon that emphasizes the central importance of narcotic receptor occupation. It is postulated that the high rate of relapse of addicts after detoxification from heroin use is due to persistent derangement of the endogenous ligand-narcotic receptor system and that methadone in an adequate daily dose compensates for this defect. Some patients with long histories of heroin use and subsequent rehabilitation on a maintenance program do well when the treatment is terminated. The majority, unfortunately, experience a return of symptoms after maintenance is stopped. The treatment, therefore, is corrective but not curative for severely addicted persons. A major challenge for future research is to identify the specific defect in receptor function and to repair it. Meanwhile, methadone maintenance provides a safe and effective way to normalize the function of otherwise intractable narcotic addicts.

Citing Articles

Methadone and neonatal abstinence syndrome (NAS): what we think we know, but do not.

McCarthy J, Finnegan L Front Pediatr. 2024; 11:1316583.

PMID: 38188918 PMC: 10768019. DOI: 10.3389/fped.2023.1316583.


A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder.

Cernasev A, Hohmeier K, Frederick K, Jasmin H, Gatwood J Explor Res Clin Soc Pharm. 2022; 2:100029.

PMID: 35481114 PMC: 9029901. DOI: 10.1016/j.rcsop.2021.100029.


Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway.

Chalabianloo F, Fadnes L, Hoiseth G, Ohldieck C, Vold J, Aas C Subst Abuse Treat Prev Policy. 2021; 16(1):39.

PMID: 33941217 PMC: 8091668. DOI: 10.1186/s13011-021-00367-w.


Opioid Use Disorders in People Living with HIV/AIDS: A Review of Implications for Patient Outcomes, Drug Interactions, and Neurocognitive Disorders.

Cernasev A, Veve M, Cory T, Summers N, Miller M, Kodidela S Pharmacy (Basel). 2020; 8(3).

PMID: 32932786 PMC: 7559328. DOI: 10.3390/pharmacy8030168.


Against Repurposing Methadone for Glioblastoma Therapy.

Vatter T, Klumpp L, Ganser K, Stransky N, Zips D, Eckert F Biomolecules. 2020; 10(6).

PMID: 32560384 PMC: 7356722. DOI: 10.3390/biom10060917.